Dr Jane Tiller is a lawyer, genetic counsellor and public health researcher. She is Ethical, Legal & Social Adviser in Public Health Genomics at Monash University, and a National Health and Medical Research Council Investigator Grant holder. Jane is passionate about the use of genomics to prevent disease, and in delivering equitable access to preventive genetic information at the population level. She is co-lead of DNA Screen, a world-first study piloting the offer of preventive DNA screening to the Australian adult population. DNA Screen has tested over 10,000 young people for genetic high risk of medically actionable conditions such as cancer and heart disease, finding about 2% of participants had genetic high risk. Jane is leading efforts to secure Commonwealth Government funding to expand the DNA Screen program, with the eventual goal of the development of a public health population screening program for disease prevention based on high genetic risk.

Drawing on almost two decades of experience in paediatric ophthalmology, alongside her research into childhood myopia, Dr Loren Rose explained that the program reflects both her clinical expertise and her long-standing passion for education. She said the rapid advances in myopia management have created a need for practical, accessible learning resources that busy clinicians can easily incorporate into practice.

To mark International Clinical Trials Day 2026, Australian Health Journal commences a 4 part special series leaving up to 20th May. Through conversations with leading researchers, clinicians and trial organisations, the series highlights achievements in the year that was for clinical trials.
Negative results in a clinical trial can be extremely valuable — both scientifically and ethically. A “negative result” usually means the treatment being tested did not work better than the standard treatment, placebo, or expected outcome.

Negative results in a clinical trial can be extremely valuable — both scientifically and ethically. A “negative result” usually means the treatment being tested did not work better than the standard treatment, placebo, or expected outcome.